by Eleftherios P
Mamounas, Hanna Bandos, Barry C Lembersky, Jong-Hyeon Jeong, Charles E Geyer,
Priya Rastogi, Louis Fehrenbacher, Mark L Graham, Stephen K Chia, Adam M
Brufsky, Janice M Walshe, Gamini S Soori, Shaker R Dakhil, Thomas E Seay, James
L Wade, Edward C McCarron, Soonmyung Paik, Sandra M Swain, D Lawrence
Wickerham, Norman Wolmark
The Lancet Oncology: Volume 20, issue 1, P88-99,
January 01, 2019
After 5 years of
aromatase inhibitor-based therapy, 5 years of letrozole therapy did not
significantly prolong disease-free survival compared with placebo. Careful
assessment of potential risks and benefits is required before recommending
extended letrozole therapy to patients with early-stage breast cancer.
